IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Burkitt-Like Lymphoma With 11q Aberration
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Burkitt-Like Lymphoma With 11q Aberration cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Blinatumomab M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Inotuzumab Ozogamicin M.D. Anderson Cancer Center | Phase 1/2 | CCC |
View all 9 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →